Post Marketing Surveillance To Observe Safety And Efficacy Of Duavive

Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

Timeframe: Baseline up to 28 days after last dose of study drug (up to 22 months)

Number of Participants With Treatment Related Adverse Events (AEs) and Serious Adverse Events (SAEs)

Timeframe: Baseline up to 28 days after last dose of study drug (up to 22 months)

Number of Participants Classified According to Measures Taken for Adverse Events

Timeframe: Baseline up to 28 days after last dose of study drug (up to 22 months)

Number of Participants With Change From Baseline in Moderate to Severe Vasomotor Symptoms Associated With Menopause at Month 3

Timeframe: Baseline, Month 3

Number of Participants With Change From Baseline in Moderate to Severe Vasomotor Symptoms Associated With Menopause at Month 6

Timeframe: Baseline, Month 6

Percentage of Participants With Improvement From Baseline in Moderate to Severe Vasomotor Symptoms Associated With Menopause at Last Visit

Timeframe: Baseline, Last visit (last visit was anytime up to a maximum of Month 21)

Number of Participants With Prevention of Post-menopausal Osteoporosis at Month 3